Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

HIV Infection

Free Subscription Articles published in Nat Med Retrieve available abstracts of 45 articles: HTML format

Single Articles

November 2023
1. 
   Viral, cellular and immune aspects of non-suppressible HIV-1 viremia.
   Nat Med. 2023 Nov 23. doi: 10.1038/s41591-023-02688.
   PubMed    
   
   
   
2. MOHAMMADI A, Etemad B, Zhang X, Li Y, et al
   Viral and host mediators of non-suppressible HIV-1 viremia.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02611.
   PubMed     Abstract available
   
   
   
3. 
   Determining the longevity and dynamics of HIV-1 neutralizing activity.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02592.
   PubMed    
   
   
   
4. SCHOMMERS P, Kim DS, Schlotz M, Kreer C, et al
   Dynamics and durability of HIV-1 neutralization are determined by viral replication.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02582.
   PubMed     Abstract available
   
   
   
5. ZHANG L, Iannuzzi S, Chaturvedula A, Irungu E, et al
   Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02615.
   PubMed     Abstract available
   
   
   
6. SHAHMANESH M, Chimbindi N, Cowan FM
   Person-centered HIV PrEP for cisgender women.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02618.
   PubMed    
   
   
   October 2023
7. EMIRU T, Getachew D, Murphy M, Sedda L, et al
   Evidence for a role of Anopheles stephensi in the spread of drug and diagnosis-resistant malaria in Africa.
   Nat Med. 2023 Oct 26. doi: 10.1038/s41591-023-02641.
   PubMed     Abstract available
   
   
   
8. MOORE M, Stansfield S, Donnell DJ, Boily MC, et al
   Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
   Nat Med. 2023 Oct 5. doi: 10.1038/s41591-023-02564.
   PubMed     Abstract available
   
   
   
9. DASHTI A, Sukkestad S, Horner AM, Neja M, et al
   AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
   Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02570.
   PubMed     Abstract available
   
   
   September 2023
10. GUNST JD, Hojen JF, Pahus MH, Rosas-Umbert M, et al
    Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
    Nat Med. 2023 Sep 11. doi: 10.1038/s41591-023-02547.
    PubMed     Abstract available
    
    
    August 2023
11. ZHANG Y, Li J, Xie Y, Wu D, et al
    Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02519.
    PubMed     Abstract available
    
    
    
12. BRANCHE AR, Rouphael NG, Diemert DJ, Falsey AR, et al
    Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Nat Med. 2023 Aug 28. doi: 10.1038/s41591-023-02503.
    PubMed     Abstract available
    
    
    
13. MULIYIL S
    Balancing the risks of HIV transmission at low viral load.
    Nat Med. 2023 Aug 3. doi: 10.1038/d41591-023-00068.
    PubMed    
    
    
    July 2023
14. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A
    Community-engaged Mpox vaccination provides lessons for equitable health care in the United States.
    Nat Med. 2023 Jul 19. doi: 10.1038/s41591-023-02447.
    PubMed    
    
    
    
15. SERRANO-VILLAR S, Tincati C, Raju SC, Saenz JS, et al
    Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.
    Nat Med. 2023;29:1738-1749.
    PubMed     Abstract available
    
    
    June 2023
16. TELFORD E, Grinsztejn B, Olsen IC, Pulik N, et al
    The international Unity study for antivirals against mpox is a blueprint for future epidemics.
    Nat Med. 2023 Jun 30. doi: 10.1038/s41591-023-02393.
    PubMed    
    
    
    
17. LISCO A, Lange C, Manion M, Kuriakose S, et al
    Immune reconstitution inflammatory syndrome drives emergence of HIV drug resistance from multiple anatomic compartments in a person living with HIV.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02387.
    PubMed     Abstract available
    
    
    
18. 
    Local immune activation shapes systemic HIV reservoirs.
    Nat Med. 2023;29:1326-1327.
    PubMed    
    
    
    May 2023
19. CARVALHO T
    First two patients receive CAR T cell therapy for HIV.
    Nat Med. 2023 May 9. doi: 10.1038/d41591-023-00042.
    PubMed    
    
    
    March 2023
20. ESMAIL A, Randall P, Oelofse S, Tomasicchio M, et al
    Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial.
    Nat Med. 2023 Mar 9. doi: 10.1038/s41591-023-02247.
    PubMed     Abstract available
    
    
    February 2023
21. 
    HIV-1 cure after CCR5Delta32/Delta32 allogeneic hematopoietic stem cell transplantation.
    Nat Med. 2023 Feb 27. doi: 10.1038/s41591-023-02215.
    PubMed    
    
    
    
22. JENSEN BO, Knops E, Cords L, Lubke N, et al
    In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32/Delta32 allogeneic hematopoietic stem cell transplantation.
    Nat Med. 2023 Feb 20. doi: 10.1038/s41591-023-02213.
    PubMed     Abstract available
    
    
    January 2023
23. MCKENNA L, Frick M, Angami K, Dubula V, et al
    The 1/4/6x24 campaign to cure tuberculosis quickly.
    Nat Med. 2023 Jan 10. doi: 10.1038/s41591-022-02136.
    PubMed    
    
    
    
24. TAN ST, Kwan AT, Rodriguez-Barraquer I, Singer BJ, et al
    Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.
    Nat Med. 2023 Jan 2. doi: 10.1038/s41591-022-02138.
    PubMed     Abstract available
    
    
    December 2022
25. KEUROGHLIAN AS, Keatley J, Shaikh S, Radix AE, et al
    The context, science and practice of gender-affirming care.
    Nat Med. 2022 Dec 15. doi: 10.1038/s41591-022-02082.
    PubMed    
    
    
    October 2022
26. BAILON L, Llano A, Cedeno S, Escriba T, et al
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2022 Oct 27. pii: 10.1038/s41591-022-02060.
    PubMed     Abstract available
    
    
    
27. GUNST JD, Pahus MH, Rosas-Umbert M, Lu IN, et al
    Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
    Nat Med. 2022 Oct 17. pii: 10.1038/s41591-022-02023.
    PubMed     Abstract available
    
    
    August 2022
28. GILBERT PB, Huang Y, deCamp AC, Karuna S, et al
    Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.
    Nat Med. 2022 Aug 22. pii: 10.1038/s41591-022-01953.
    PubMed     Abstract available
    
    
    
29. DE BAETSELIER I, Van Dijck C, Kenyon C, Coppens J, et al
    Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium.
    Nat Med. 2022 Aug 12. pii: 10.1038/s41591-022-02004.
    PubMed     Abstract available
    
    
    July 2022
30. BEKKER LG
    Long-acting agents for HIV treatment and prevention.
    Nat Med. 2022 Jul 22. pii: 10.1038/s41591-022-01917.
    PubMed    
    
    
    June 2022
31. TEGALLY H, Moir M, Everatt J, Giovanetti M, et al
    Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.
    Nat Med. 2022 Jun 27. pii: 10.1038/s41591-022-01911.
    PubMed     Abstract available
    
    
    May 2022
32. JULG B, Stephenson KE, Wagh K, Tan SC, et al
    Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Nat Med. 2022 May 12. pii: 10.1038/s41591-022-01815.
    PubMed     Abstract available
    
    
    April 2022
33. CASAZZA JP, Cale EM, Narpala S, Yamshchikov GV, et al
    Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
    Nat Med. 2022 Apr 11. pii: 10.1038/s41591-022-01762.
    PubMed     Abstract available
    
    
    March 2022
34. ARSENAULT C, Gage A, Kim MK, Kapoor NR, et al
    COVID-19 and resilience of healthcare systems in ten countries.
    Nat Med. 2022 Mar 14. pii: 10.1038/s41591-022-01750.
    PubMed     Abstract available
    
    
    February 2022
35. O'LEARY K
    HIV variant causes concern.
    Nat Med. 2022 Feb 14. pii: 10.1038/d41591-022-00034.
    PubMed    
    
    
    January 2022
36. MILLER JS, Davis ZB, Helgeson E, Reilly C, et al
    Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial.
    Nat Med. 2022 Jan 31. pii: 10.1038/s41591-021-01651.
    PubMed     Abstract available
    
    
    
37. O'LEARY K
    HIV and skin cancer risk.
    Nat Med. 2022 Jan 6. pii: 10.1038/d41591-022-00001.
    PubMed    
    
    
    December 2021
38. 
    Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    PubMed    
    
    
    
39. DEEKS SG, Archin N, Cannon P, Collins S, et al
    Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.
    Nat Med. 2021 Dec 1. pii: 10.1038/s41591-021-01590.
    PubMed     Abstract available
    
    
    
40. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    PubMed    
    
    
    
41. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    PubMed     Abstract available
    
    
    November 2021
42. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed     Abstract available
    
    
    October 2021
43. BLAZKOVA J, Gao F, Marichannegowda MH, Justement JS, et al
    Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy.
    Nat Med. 2021 Oct 28. pii: 10.1038/s41591-021-01503.
    PubMed     Abstract available
    
    
    
44. STEPHENSON KE, Julg B, Tan CS, Zash R, et al
    Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
    Nat Med. 2021 Oct 7. pii: 10.1038/s41591-021-01509.
    PubMed     Abstract available
    
    
    
45. MATTHEWS RP, Patel M, Barrett SE, Haspeslagh L, et al
    Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01479.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.